{
  "nctId": "NCT02881957",
  "briefTitle": "Hypovitaminosis D in Neurocritical Patients",
  "officialTitle": "Randomized Clinical Trial of Hypovitaminosis D Treatment in the Neurocritical Care Unit",
  "protocolDocument": {
    "nctId": "NCT02881957",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2017-08-30",
    "uploadDate": "2020-08-02T22:03",
    "size": 514312,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02881957/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2",
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 274,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-10-10",
    "completionDate": "2018-10-10",
    "primaryCompletionDate": "2018-10-10",
    "firstSubmitDate": "2016-08-24",
    "firstPostDate": "2016-08-29"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Patients \\>18 years of age\n* Patients admitted to the neurosurgery or neurology services\n* Patients admitted to a critical care unit\n* Informed consent\n* Expected to stay in the ICU for 48 hours or more\n* Vitamin D deficiency (\\<20ng/mL)\n\nExclusion Criteria:\n\n* Patients where a vitamin D level was not drawn within 48 hours of admission\n* Patients not randomized within 48 hours of admission\n* Readmitted patients to the critical care unit\n* Lack of informed consent\n* Prior supplementation with vitamin D\n* Severely impaired gastrointestinal function\n* Other trial participation\n* Pregnant or lactating women\n* Hypercalcemia (total calcium of \\>10.6 mg/dL or ionized serum calcium of \\>5.4 mg/dL\n* Tuberculosis history or clinical exam\n* Sarcoidosis history or clinical exam\n* Nephrolithiasis within the prior year\n* Patients not deemed suitable for study participation (ie, psychiatric disease, living remotely from the clinic, or prisoner status)\n* Pregnant or nursing women",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Intent-to-treat Hospital Length-of-stay",
        "description": "Intent-to-treat hospital length-of-stay",
        "timeFrame": "Until discharge"
      },
      {
        "measure": "As-treated Hospital Length of Stay",
        "description": "Two-sided t-test evaluated comparing length of stay in vitamin D3 vs. placebo treated patients utilizing patients after randomization, factoring excluded patients (e.g., as-treated) using a p\\<0.05 as significant.",
        "timeFrame": "Until discharge"
      }
    ],
    "secondary": [
      {
        "measure": "Intent-to-treat ICU Length of Stay",
        "description": "Two-sided t-test evaluated comparing length of stay within the ICU specifically in vitamin D3 vs. placebo treated patients utilizing patients after randomization (e.g., intent-to-treat) using a p\\<0.05 as significant.",
        "timeFrame": "Until discharge"
      },
      {
        "measure": "As-treated ICU Length of Stay",
        "description": "Two-sided t-test evaluated comparing length of stay within the ICU specifically in vitamin D3 vs. placebo treated patients utilizing patients after randomization but excluding patients who did not receive treatment (e.g., as-treated) using a p\\<0.05 as significant.",
        "timeFrame": "Until discharge"
      },
      {
        "measure": "In-hospital Mortality",
        "description": "In-hospital mortality",
        "timeFrame": "Until discharge"
      },
      {
        "measure": "Number of Participants With Study Drug Related Adverse Events",
        "description": "The occurrence of patients who suffered mortality, adverse events or severe adverse events, related specifically to the study drug was monitored. Severe adverse events are defined using common terminology criteria for adverse events (CTCAE) grade 3 or higher specific to vitamin D from time of study drug administration to discharge.",
        "timeFrame": "Until discharge"
      },
      {
        "measure": "Number of Participants With Sepsis",
        "description": "Diagnosis of sepsis",
        "timeFrame": "Until discharge"
      },
      {
        "measure": "Number of Participants With Pneumonia",
        "description": "Pneumonia diagnosis",
        "timeFrame": "Until discharge"
      },
      {
        "measure": "Number of Participants With Urinary Tract Infection",
        "description": "Urinary tract infection diagnosis",
        "timeFrame": "Until discharge"
      },
      {
        "measure": "Number of Participants With Deep Vein Thrombosis",
        "description": "Deep vein thrombosis diagnosis",
        "timeFrame": "Until discharge"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 8,
      "otherCount": 0,
      "totalCount": 10
    },
    "studyDesign": {
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 99,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:35.876Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}